Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626530 · ClinicalTrials.gov registry record · Phase 4
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
A Phase 4 study of Cytomegalovirus Infections and Neutropenia, sponsored by Tufts Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05626530: Recruiting Phase 4 study of Cytomegalovirus Infections and Neutropenia, sponsored by Tufts Medical Center.
NCT05626530 is a Phase 4 study of Cytomegalovirus Infections and Neutropenia that is actively recruiting participants, run by Tufts Medical Center. The registered enrollment target is 25 participants, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05626530, a Phase 4 study of Cytomegalovirus Infections and Neutropenia, is actively recruiting participants, sponsored by Tufts Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient. This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.
Primary Outcome
Proportion of patients with relapsing CMV disease up to 6 months after starting drug
Conditions Studied
Interventions
- DRUG Letermovir
Study Locations (1)
Massachusetts
- Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2025-12-15 |
| Phase | Phase 4 |
What NCT05626530 shows while recruiting
NCT05626530 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (88% lower).
The record links to 4 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which Letermovir is the first listed.
NCT05626530 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05626530 about?
NCT05626530 is a clinical study titled "Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients". This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient. This study is an open label trial in which L...
What is the current status of trial NCT05626530?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2023-02-02. Estimated completion is 2025-12-15.
What conditions does trial NCT05626530 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections, Neutropenia, Infection in Solid Organ Transplant Recipients, Antiviral Toxicity.
What interventions are being tested in trial NCT05626530?
The interventions under investigation include: Letermovir (DRUG).
Who is sponsoring clinical trial NCT05626530?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05626530 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05626530's enrollment target sits among peer trials
25 18th of 24 higher than 5 of 24 other Cytomegalovirus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cytomegalovirus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
RECRUITING · Phase 2
-
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
RECRUITING
-
R-MVST Cells for Treatment of Viral Infections
RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
RECRUITING · Phase 2
-
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI